Literature DB >> 34893532

Analgesic Use and Circulating Estrogens, Androgens, and Their Metabolites in the Women's Health Initiative Observational Study.

Lauren M Hurwitz1, Aladdin H Shadyab2, Fred K Tabung3, Garnet L Anderson4, Nazmus Saquib5, Robert B Wallace6, Robert A Wild7, Ruth M Pfeiffer1, Xia Xu8, Britton Trabert1.   

Abstract

Though studies have observed inverse associations between use of analgesics (aspirin, NSAIDs, and acetaminophen) and the risk of several cancers, the potential biological mechanisms underlying these associations are unclear. We investigated the relationship between analgesic use and serum concentrations of estrogens, androgens, and their metabolites among postmenopausal women to provide insights on whether analgesic use might influence endogenous hormone levels, which could in turn influence hormone-related cancer risk. The study included 1,860 postmenopausal women from two case-control studies nested within the Women's Health Initiative Observational Study. Analgesic use was reported at study baseline. Fifteen estrogens and estrogen metabolites and 12 androgens and androgen metabolites were quantified in baseline serum by LC/MS-MS. Linear regression with inverse probability weighting, stratified by menopausal hormone therapy (MHT) use, was used to estimate adjusted geometric mean concentrations of each hormone by analgesic use. Among women not currently using MHT (n = 951), low-dose aspirin (<100 mg) use was associated with a higher serum concentration of estrone, estradiol, and 2, 4, and 16 hydroxylated metabolites. Use of regular-dose aspirin (≥100 mg), non-aspirin NSAIDs, and acetaminophen was not associated with serum concentrations of estrogens, androgens, or their metabolites. This study highlights the importance of examining aspirin use by dose and suggests that low-dose aspirin may influence endogenous estrogen concentrations. PREVENTION RELEVANCE: This study explores a potential pathway by which analgesic medications such as aspirin may prevent hormone-related cancers. The findings support a positive association between low-dose aspirin use and endogenous estrogens, indicating that further elucidation of the interplay between low-dose aspirin, estrogen concentrations, and cancer risk is needed. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34893532      PMCID: PMC8898279          DOI: 10.1158/1940-6207.CAPR-21-0264

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  50 in total

1.  NSAID use and breast cancer risk in the VITAL cohort.

Authors:  Ann Ready; Christine M Velicer; Anne McTiernan; Emily White
Journal:  Breast Cancer Res Treat       Date:  2007-08-03       Impact factor: 4.872

2.  Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT.

Authors:  Cher M Dallal; Jeffrey A Tice; Diana S M Buist; Douglas C Bauer; James V Lacey; Jane A Cauley; Trisha F Hue; Andrea Lacroix; Roni T Falk; Ruth M Pfeiffer; Barbara J Fuhrman; Timothy D Veenstra; Xia Xu; Louise A Brinton
Journal:  Carcinogenesis       Date:  2013-11-08       Impact factor: 4.944

3.  Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial.

Authors:  Catherine Duggan; Ching-Yun Wang; Liren Xiao; Anne McTiernan
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-12

4.  Estrogen metabolism and risk of breast cancer in postmenopausal women.

Authors:  Barbara J Fuhrman; Catherine Schairer; Mitchell H Gail; Jennifer Boyd-Morin; Xia Xu; Laura Y Sue; Saundra S Buys; Claudine Isaacs; Larry K Keefer; Timothy D Veenstra; Christine D Berg; Robert N Hoover; Regina G Ziegler
Journal:  J Natl Cancer Inst       Date:  2012-01-09       Impact factor: 13.506

Review 5.  Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.

Authors:  Edgar S Díaz-Cruz; Robert W Brueggemeier
Journal:  Anticancer Agents Med Chem       Date:  2006-05       Impact factor: 2.505

Review 6.  Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis.

Authors:  Ya-shuang Zhao; Sui Zhu; Xiang-wei Li; Fan Wang; Fu-lan Hu; Dan-dan Li; Wen-cui Zhang; Xia Li
Journal:  Breast Cancer Res Treat       Date:  2008-11-02       Impact factor: 4.872

7.  Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.

Authors:  Elizabeth L Barry; Veronika Fedirko; Karan Uppal; Chunyu Ma; Ken Liu; Leila A Mott; Janet L Peacock; Michael N Passarelli; John A Baron; Dean P Jones
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-12

8.  Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.

Authors:  Britton Trabert; Elizabeth M Poole; Emily White; Kala Visvanathan; Hans-Olov Adami; Garnet L Anderson; Theodore M Brasky; Louise A Brinton; Renee T Fortner; Mia Gaudet; Patricia Hartge; Judith Hoffman-Bolton; Michael Jones; James V Lacey; Susanna C Larsson; Gerardo G Mackenzie; Leo J Schouten; Dale P Sandler; Katie O'Brien; Alpa V Patel; Ulrike Peters; Anna Prizment; Kim Robien; V Wendy Setiawan; Anthony Swerdlow; Piet A van den Brandt; Elisabete Weiderpass; Lynne R Wilkens; Alicja Wolk; Nicolas Wentzensen; Shelley S Tworoger
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

9.  Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015.

Authors:  Mark Stuntz; Brent Bernstein
Journal:  Prev Med Rep       Date:  2016-12-28

10.  Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.

Authors:  Roni T Falk; Louise A Brinton; Joanne F Dorgan; Barbara J Fuhrman; Timothy D Veenstra; Xia Xu; Gretchen L Gierach
Journal:  Breast Cancer Res       Date:  2013-04-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.